Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

UK biotech Synairgen is pushing ahead with a phase 3 trial ... its inhaled version through its paces in trials involving subjects with asthma and chronic obstructive pulmonary disease (COPD).

Inhalers and nebulizers play a key role in delivering medication to the lungs, making it easier for people with breathing ...

UK-based Verona Pharma has scored a key win in a phase 3 ... COPD market in late 2023 or 2024. There's another hurdle to overcome before a filing can take place – the results of the companion ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala ...

FEV 1: Forced expiratory volume in 1 s ... University of Groningen, The Netherlands 3 Department of Human Movement Sciences, University Medical Centre Groningen, University of Groningen, The ...

After months of silence, we now know that One-Punch Man season 3 is releasing in 2025. Alongside that, there's plenty of news about the superhero anime's 10th anniversary plans. From what we've ...

and Blood Institute's Expert Panel Report 3; in addition, the pharmacodynamic and pharmacokinetic basis for potential clinical differences among inhaled corticosteroids is discussed. Data Sources ...

Aerosol delivery devices are hand-held, portable drug delivery devices. They consist of suspension of solid or liquid particles in a carrier gas, which makes feasible for treatment of respiratory and ...